Anzeige
Mehr »
Login
Samstag, 25.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PBJD | ISIN: US4158581094 | Ticker-Symbol:
NASDAQ
24.05.24
22:00 Uhr
17,890 US-Dollar
+0,420
+2,40 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
HARROW INC Chart 1 Jahr
5-Tage-Chart
HARROW INC 5-Tage-Chart

Aktuelle News zur HARROW Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.05.Earnings call: Harrow Inc. reports robust revenue growth in Q1 20242
14.05.Harrow Inc reports results for the quarter ended in March - Earnings Summary2
13.05.HARROW, INC. - 8-K, Current Report1
13.05.Harrow Health Non-GAAP EPS of -$0.28 misses by $0.07, revenue of $34.59M misses by $2.68M2
13.05.Harrow Health, Inc. Announces First Quarter 2024 Financial Results61NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2024. The Company also...
► Artikel lesen
12.04.HROW, HCAT and EGRX are among after hour movers3
25.03.Harrow CEO Mark Baum buys $104k in company stock2
22.03.Opaleye Management buys $488k of Harrow Inc. shares1
21.03.Earnings call: Harrow Health reports record revenues, optimistic outlook2
20.03.Why Is Harrow (HROW) Stock Up 5% Today?1
20.03.Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session8
20.03.Harrow Health Non-GAAP EPS of -$0.20 misses by $0.15, revenue of $36.36M misses by $1.5M1
19.03.Harrow Inc reports results for the quarter ended in December - Earnings Summary-
19.03.Harrow Health, Inc. Announces Fourth Quarter and Year-End 2023 Financial Results114NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2023. The Company also...
► Artikel lesen
19.03.Harrow: Q4 Earnings Insights1
19.03.HARROW, INC. - 8-K, Current Report1
19.03.HARROW, INC. - 10-K, Annual Report1
18.03.Harrow Health Q4 2023 Earnings Preview1
18.03.Earnings Preview: Harrow Health1
21.02.Here's How Harrow (HROW) Weighed on SRK Capital's Performance1
Seite:  Weiter >>
29 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1